BiotechTube

liraglutide + placebo + liraglutide + placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolism and Nutrition Disorder

Conditions

Metabolism and Nutrition Disorder, Obesity

Trial Timeline

Jun 1, 2011 → Mar 2, 2015

NCT ID
NCT01272219

About liraglutide + placebo + liraglutide + placebo

liraglutide + placebo + liraglutide + placebo is a phase 3 stage product being developed by Novo Nordisk for Metabolism and Nutrition Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01272219. Target conditions include Metabolism and Nutrition Disorder, Obesity.

What happened to similar drugs?

5 of 19 similar drugs in Metabolism and Nutrition Disorder were approved

Approved (5) Terminated (2) Active (14)
✅Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Fluvastatin sodiumNovartisApproved
🔄liraglutide + placeboNovo NordiskPhase 3
🔄Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
🔄Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02092896Phase 3Completed
NCT01272219Phase 3Completed
NCT00943501Phase 1Completed

Competing Products

20 competing products in Metabolism and Nutrition Disorder

See all competitors
ProductCompanyStageHype Score
mRNA-3704ModernaPhase 2
0
E2609EisaiPhase 1
29
E2006EisaiPhase 1
29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)AstraZenecaPhase 1
29
Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
43
Rabeprazole or Esomeprazole or LanzoprazoleAstraZenecaPre-clinical
26
cyclosporine micro-emulsionNovartisApproved
35
Fluvastatin sodiumNovartisApproved
43
NNC0165-1562 + placeboNovo NordiskPhase 1
29
liraglutideNovo NordiskPhase 1
29
NNC9204-0530 + placeboNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 3
40
Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
40
Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
40
liraglutide + orlistat + placeboNovo NordiskPhase 2
35
NNC 0070-0002-0453 + '2-0453 + placeboNovo NordiskPhase 1
21
NNC0194-0499 + PlaceboNovo NordiskPhase 1
29
Semaglutide + PlaceboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40